Search-and-Replace Gene Editing: The Era of Prime Editing
1. Limitations of CRISPR: The Challenge of Sub‑optimal Precision
The conventional CRISPR‑Cas9 system sparked a revolution in genome editing, but it relies on a double‑strand break (DSB) that cleaves both DNA strands. During cellular repair, unpredictable mutations can arise, and the requirement for a specific protospacer adjacent motif (PAM) restricts target accessibility. Consequently, achieving both safety and high precision remains a significant hurdle.
2. Prime Editing: A Powerful Collaboration Between Cas9 Nickase and Reverse Transcriptase
Prime Editing converts gene correction from a “cut” to a “rewrite” paradigm. It couples a Cas9 nickase that makes a single‑strand incision with an engineered reverse transcriptase (RT) that writes new genetic information. A sophisticated guide RNA, the prime editing guide RNA (pegRNA), both locates the target site and supplies the desired DNA template. This enables precise modification of specific nucleotides without generating a full DSB.
3. First In‑Human Clinical Success: Hope Beyond the Laboratory
The technological momentum continued with innovative delivery platforms such as nanoparticles and split‑viral systems, allowing Prime Editing to enter its first human clinical trial. Functional recovery was observed in the initial patient, and to date the intervention has demonstrated a favorable safety profile without serious adverse events, raising unprecedented optimism in the medical community.
4. A New Chapter in Therapeutics: Toward Curative Gene Therapy
This clinical milestone signals that gene therapy is transitioning from disease management to potential cure. With further improvements in efficiency and delivery, Prime Editing could become a universal platform capable of addressing thousands of genetic disorders. In the future, receiving personalized correction therapies may become as routine for rare disease patients as corrective eye surgery is today.
The advent of CRISPR systems has transformed genome editing, offering unparalleled efficiency and versatility with wide therapeutic potential. However, conventional CRISPR systems face key limitations, including unpredictable and imprecise outcomes during repair of double stranded breaks and reliance on specific protospacer adjacent motif sequences. In response, prime editing (PE) has emerged as a powerful alternative, enabling precise custom edits using a fusion of Cas9 nickase and an engineered reverse transcriptase (RT) together with a prime editing guide RNA (pegRNA) that encodes the desired repair template. PE enables edits to be installed at or downstream of the target site, expanding the range of targetable sequences. Since its inception, PE has undergone extensive optimisation, including Cas variant selection, RT engineering, and pegRNA improvements. In parallel, advances in delivery, including nanoparticles and split viral systems, have accelerated translation across preclinical disease models. Notably, PE has now entered the clinic, with the first in-human study reporting functional restoration with a promising safety profile to date. Here, we summarise recent mechanistic insights, architectural innovations, and therapeutic applications of PE, and discuss the remaining challenges in efficiency, delivery, and safety that will shape broader clinical impact.
The risk of off‑target cuts by gene‑editing nucleases has been dramatically reduced. With a safer and more precise technology, we can directly rewrite the human genome, breaking the hereditary chain of rare genetic diseases and enabling a healthier future for all.